We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

ERBA MANNHEIM

Erba Mannheim is an IVD solutions provider focused on improving health outcomes in developing nations. Originally fou... read more Featured Products: More products

Download Mobile App





ERBA Mannheim Launches CE Marked COVID-19 IgM Antibody ELISA Kit

By LabMedica International staff writers
Posted on 25 Jun 2020
Erba Mannheim (London, England) has launched the ErbaLisa COVID-19 IgM ELISA kit for the detection of IgM antibodies to SARS-CoV-2 in response to the ongoing COVID-19 pandemic.

The ready-to-use ELISA kits allows for the qualitative and semi-quantitative detection of IgG/M antibodies to SARS-CoV-2 in human serum. More...
Since IgM antibodies are produced first and detectable during disease onset, using the new assay in combination with Erba's existing ErbaLisa COVID-19 IgG ELISA can detect both early and late phases of the immune response.

Erba's solid phase assays use proven technology, and total incubation time is 50 minutes at room temperature with a simple one step serum dilution. ErbaLisa COVID-19 assays are built for superior performance and reliable interpretation of results. With full CE certification, the reliable and automation-friendly COVID-19 ELISA kits are now available through Erba's global distribution network, including in the US.

"We are working tirelessly to offer more options to clinicians and laboratories with which to gain an advantage in responding to this unprecedented global health crisis," said Nikhil Vazirani, MD of Erba Mannheim.



Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Online QC Software
Acusera 24•7
Prefilled Tubes
Prefilled 5.0ml Tubes
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.